Toxicity management of immunotherapy for patients with metastatic melanoma

Annals of Translational Medicine

Volumn 4, Issue 14, 2016, Pages

  Linardou, Helena ^a   Gogas, Helen ^b  

^a METROPOLITAN HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Checkpoint inhibitors; Immune related adverse events (irAEs); Immunotherapy; Metastatic melanoma; Toxicity

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; LOPERAMIDE; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; STEROID;

AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; COLITIS; COUGHING; DIARRHEA; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EYE TOXICITY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; METASTATIC MELANOMA; NEPHROTOXICITY; NEUROPATHY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; RASH; REVIEW; SKIN TOXICITY; VITILIGO;

EID: 85006190127     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.07.10     Document Type: Review

References (51)

1. Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med 2016;14:20.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
5. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
7. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
8. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18.
9. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84.
10. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372:2521-32.
11. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
12. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamous cell non-small cell lung cancer. N Engl J Med 2015;373:123-35.
13. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015;372:2018-28.
14. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20.
15. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
16. Ibrahim RA, Berman DB, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011;29:abstr 8583.
17. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immunerelated toxicities. Transl Lung Cancer Res 2015;4:560-75.
18. Keytruda® [package insert]. Whitehouse Station, NJ, USA: Merck & Co., Inc., 2015. Available online: http:// dailymed.nlm.nih.gov/dailymed/drugInfo
19. Opdivo® [package insert]. Princeton, NJ, USA: Bristol- Myers Squibb Company, 2015. Available online: http:// dailymed.nlm.nih.gov/dailymed/drugInfo
20. YERVOY™ (ipilimumab) US Prescribing Information: Risk Evaluation and Mitigation Strategy (REMS). Princeton, NJ, USA: Bristol-Myers Squibb Company, 2015, Available online: http://www.hcp.yervoy.com/
21. Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013;18:733-43.
22. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
23. Wolchok J, Neyns B, Linette B, et al. Ipilimumab monotherapy in patients with previously treated, advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64.
24. Dummer R, Maio M, Hamid O, et al. Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. Proceedings of the 14th Perspectives in Melanoma. Amsterdam, The Netherlands, 2010:abstract P-0004.
25. Lebbé C, O'Day SJ, Sileni VC, et al. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma. Proceedings of the 12th Perspectives in Melanoma. New York, NY, USA, 2008:abstract O-015.
26. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012;6:53-66.
27. Rubin KM. Managing immune-related adverse events to ipilimumab: a nurse's guide. Clin J Oncol Nurs 2012;16:E69-75.
28. Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a singleinstitution hospital-based observational cohort study. Ann Oncol 2010;21:409-14.
29. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40.
30. O'Day S, Weber JS, Wolchok JD, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol 2011;29:abstr 8554.
31. Baurain JF, Smylie M, Ascierto PA, et al. Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. J Clin Oncol 2012; 30:abstr 8539.
32. Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013;98:1361-75.
33. Ryder M, Callahan M, Postow MA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-81.
34. Kaehler KC, Egberts F, Lorigan P, et al. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Res 2009;19:333-4.
35. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011;22:991-3.
36. Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012;30:e76-8.
37. Bot I, Blank CU, Boogerd W, et al. Neurological immunerelated adverse events of ipilimumab. Pract Neurol 2013;13:278-80.
38. Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumabinduced Ocular and Orbital Inflammation-A Case Series and Review of the Literature. Ocul Immunol Inflamm 2016;24:140-6.
39. Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis 2016;10:183-93.
40. Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy 2016;8:665-74.
41. Kourie HR, Awada G, Awada AH. Rare side-effects of checkpoint inhibitors. Curr Opin Oncol 2016;28:295-305.
42. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-25.
43. Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med 2015;373:288-90.
44. Nishino M, Chambers ES, Chong CR, et al. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res 2016;4:289-93.
45. Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol 2016;28:306-13.
46. Baroudjian B, Lourenco N, Pagès C, et al. Anti-PD1- induced collagenous colitis in a melanoma patient. Melanoma Res 2016;26:308-11.
47. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209.
48. Márquez-Rodas I, Cerezuela P, Soria A, et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267.
49. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:23-34.
50. Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol 2011;29:abstr 2505.
51. Shahabi V, Berman D, Chasalow SD, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med 2013;11:75.